New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Drs Kerri Schellenberg, Homira Osman, Erin Beattie, Hanns Lochmüller, Craig Campbell, Jean Mah as well as Stacey Lintern, Maria Masnata, Rhiannon Hicks, Corinne Kagan and Ana Stosic. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Recognizing the unique challenges of conducting clinical trials in rare diseases, including small patient populations, geographic dispersion, and limited infrastructure, the study identified key barriers across the Canadian landscape. These included burdensome feasibility processes, limited workforce capacity, lack of centralized trial visibility, and fragmented coordination among stakeholders.
In response, the NMD4C Clinical Trial Network developed targeted strategies to address these gaps, including centralized feasibility triage, a national Community of Practice, mentorship, operational support, and alignment with patient and registry infrastructure. These efforts aim to strengthen coordination, support clinical trial personnel, and improve the overall delivery of neuromuscular trials across Canada.
This work presents a practical model for building a more coordinated and sustainable clinical trial ecosystem, with the potential to improve trial readiness and access for individuals living with rare neuromuscular diseases.
Read the Full Publication
Read next...
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.
Announcing: 2026 Signals that Move Us Image Competition Winners
Research often uncovers incredible visual beauty alongside data and discovery. This year, our community highlighted that intersection through the Signals That Move Us Image Competition. We received 12 entries from our trainees, each offering a unique look at the signals, structures, and cellular dynamics driving our research. With so many strong entries, selecting the top…